DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Natalie Grover Bhanvi Satija"


3 mentions found


☆ Thousands of people in Ukraine have complex war-related injuries, says WHO
  + stars: | 2023-03-07 | by ( Natalie Grover Bhanvi Satija | Natalie Grover | Bhanvi Satija | ) www.reuters.com   time to read: +1 min
LONDON, March 7 (Reuters) - Thousands of people in Ukraine have sustained complex injuries linked to the war and need rehabilitation services and equipment to help them, a senior World Health Organization (WHO) official said on Tuesday. They include fractures, amputations, spinal cord injuries, traumatic brain injuries and burns, Dr Satish Mishra from the WHO's regional office for Europe, told a media briefing. Since then, the pandemic and the war have significantly increased the need for rehab services, he added. In comparison, about 2 in 5 people across the European region in 2019 had a health condition that could have benefited from rehabilitation services, according to Morgan. Russia calls its actions in Ukraine a "special military operation" and says it does not target civilians.
☆ Novavax sinks on concerns about COVID vaccine maker's prospects
  + stars: | 2023-03-01 | by ( Natalie Grover Bhanvi Satija | Natalie Grover | Bhanvi Satija | ) www.reuters.com   time to read: +3 min
The company — which has its COVID-19 vaccine as the only marketed product after 35 years in business — on Tuesday flagged significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi. Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. Novavax faces near-term risks as protein-based vaccines take longer to produce than mRNA-based competitors, Novavax CEO John Jacobs has said. "While there is the potential for a substantial booster market ... we don't expect Novavax to be a major player in the booster opportunity." As of last close, Novavax's U.S.-listed shares were down 97% from their February 2021 record high of $331.68.
☆ Concerns about prospects of COVID vaccine maker Novavax sink shares
  + stars: | 2023-03-01 | by ( Natalie Grover Bhanvi Satija | Natalie Grover | Bhanvi Satija | ) www.reuters.com   time to read: +3 min
The stock had dropped 26.2% to $6.83 around 8:55 ET (13:55 GMT), while its Frankfurt-listed shares slumped more than 27%. The company - whose COVID vaccine is its only marketed product after 35 years in business - on Tuesday flagged significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi. Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. Novavax faces near-term risks as protein-based vaccines take longer to produce than mRNA-based competitors, Novavax CEO John Jacobs has said. As of last close, Novavax's U.S.-listed shares are down 97% from their February 2021 record high of $331.68.
0 next >>
Total: 3